10-Q: Nevro Corp. Reports Q3 2024 Results: Revenue Declines Amid Restructuring Efforts

Nevro Corp. experienced a decrease in revenue during the third quarter of 2024, alongside ongoing restructuring initiatives aimed at improving profitability.

Summary

• Nevro Corp.'s revenue for the third quarter of 2024 was $96.9 million, a decrease of 7% compared to $103.9 million in the same period of 2023.
• The company's U.S. revenue decreased by 7% to $83.9 million, while international revenue decreased to $13.0 million.
• The decrease in revenue was primarily due to lower trial and permanent implant volumes.
• Cost of revenue decreased by 6% to $32.3 million, driven by lower unit sales and reduced product costs from the Costa Rica facility, partially offset by a $0.8 million inventory write-down.
• Gross profit decreased to $64.6 million, with a gross margin of 67%, consistent with the previous year.
• Operating expenses decreased by 16% to $78.5 million, primarily due to lower legal, marketing, and personnel expenses.
• The company recorded a gain of $1.3 million from the change in fair value of contingent consideration.
• Interest expense increased to $7.0 million due to the Braidwell Credit Agreement, partially offset by reduced interest on the 2025 Notes.
• A gain of $3.4 million was recorded from the change in fair value of warrants.
• The company reported a net loss of $15.3 million, or $0.41 per share, compared to a net loss of $23.5 million, or $0.65 per share, in the same quarter of 2023.
• For the nine months ended September 30, 2024, revenue was $303.0 million, a decrease of 2% compared to $309.0 million in the same period of 2023.
• The company recognized a restructuring charge of $10.8 million for the nine months ended September 30, 2024.
• Cash, cash equivalents, and short-term investments totaled $277.0 million as of September 30, 2024.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positives such as cost reductions and a gain from warrant valuation, the revenue decline and net loss are concerning. The company is also facing macroeconomic headwinds and competitive pressures, which contribute to a negative sentiment.

Positives

• Operating expenses decreased by 16% year-over-year, indicating cost-cutting measures are taking effect.
• The company recorded a gain of $1.3 million from the change in fair value of contingent consideration.
• A gain of $3.4 million was recorded from the change in fair value of warrants.
• Cost of revenue decreased by 6% due to lower unit sales and reduced product costs from the Costa Rica facility.
• The company has $277.0 million in cash, cash equivalents, and short-term investments.

Negatives

• Third-quarter revenue decreased by 7% year-over-year, indicating a slowdown in sales.
• The company reported a net loss of $15.3 million for the third quarter.
• Interest expense increased to $7.0 million due to the Braidwell Credit Agreement.
• The company recognized a restructuring charge of $10.8 million for the nine months ended September 30, 2024.
• Gross profit decreased to $64.6 million.

Risks

• The company's business is significantly impacted by macroeconomic conditions, including inflation, interest rates, and supply chain issues.
• The company's revenue depends on physician awareness and acceptance of its products, which can vary.
• Reimbursement and coverage decisions by third-party payors can significantly impact the company's revenue.
• The company is subject to the risk of inventory obsolescence and expiration.
• The company relies on third-party suppliers, making it vulnerable to supply shortages.
• The company may need to raise additional funds in the future, which may not be available on acceptable terms.
• The company faces significant competition in the neuromodulation market.
• Declines in the company's market capitalization could result in impairment charges to goodwill, net tangible assets or identifiable intangible assets.

Future Outlook

The company expects its cash and cash equivalents, short-term investments, and anticipated funds from receivables to be sufficient to fund operations for at least the next 12 months. They plan to continue investing in commercial infrastructure, R&D, and clinical trials. The company may also seek additional funding through equity or debt financings.

Management Comments

• Management believes the superiority of 10 kHz Therapy over traditional SCS therapies will allow them to capitalize on and expand the global SCS market.
• Management intends to continue investing in R&D to expand into new indications and chronic pain conditions.
• Management is working to expand payor coverage to include the use of 10 kHz Therapy for the management of PDN and NSBP.

Industry Context

The company operates in the global neuromodulation market, which is estimated to be approximately $2.3 billion. The company faces competition from established players like Medtronic, Boston Scientific, and Abbott Laboratories, as well as emerging competitors. The company's focus on 10 kHz Therapy and its clinical evidence is aimed at differentiating itself in this competitive landscape.

Comparison to Industry Standards

• Nevro's 10 kHz Therapy is positioned as superior to traditional SCS therapy, with clinical trials showing it to be nearly twice as successful in treating back pain and 1.5 times as successful in treating leg pain compared to traditional SCS therapy.
• The SENZA-PDN study is one of the largest RCTs conducted in the field of spinal cord stimulation, demonstrating the efficacy of Nevro's therapy for PDN.
• The SENZA-NSRBP study supports the use of Nevro's therapy for non-surgical back pain, with 24-month results showing significant improvements in pain relief, function, and quality of life.
• Competitors like Medtronic, Boston Scientific, and Abbott Laboratories have established neuromodulation systems, but Nevro aims to differentiate itself through its proprietary 10 kHz Therapy and clinical evidence.
• Nevro's gross margin of 67% is within the range of medical device companies, but the company is working to reduce manufacturing costs to improve margins.

Legal Proceedings

• The company is involved in several pending European patent oppositions at the European Patent Office (EPO) initiated by competitors Medtronic and Boston Scientific.
• The company is involved in various legal proceedings, such as employment matters, product liability matters, and professional liability matters, which the company does not deem to be material at this stage.
• The company was involved in litigation and arbitration with Flathead Partners, which was resolved in the company's favor.

Stakeholder Impact

• Shareholders may be concerned about the revenue decline and net loss.
• Employees may be affected by the restructuring and layoffs.
• Customers may be impacted by the company's ability to deliver products and services.
• Suppliers may be affected by the company's supply chain management and purchase commitments.
• Creditors may be concerned about the company's ability to repay its debt.

Next Steps

• The company will continue to invest in commercial infrastructure and sales force.
• The company will continue to invest in R&D and clinical trials.
• The company will work to expand payor coverage for PDN and NSBP.
• The company will continue to monitor and manage its supply chain.
• The company will continue to evaluate its financial performance and may seek additional funding.

Key Dates

Keywords

spinal cord stimulation, neuromodulation, chronic pain, HFX, Senza, 10 kHz Therapy, PDN, NSBP, medical devices, restructuring, financial results